GlassScriptPhysician profile
Sheila S Janisch
NPI 1265754576
$400.49
in general payments reported to CMS, 2019-2025
11 companies · $81.49 in 2025
The $81.49 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.18 · 2022: $42.41 · 2023: $163 · 2024: $63.53 · 2025: $81.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286 · Education: $21.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.39 |
| Education | $21.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $81.49 | 2025 | |
| Collegium Pharmaceutical, INC. | $71.26 | 2022-2023 | Xtampza |
| Spr Therapeutics, INC | $52.87 | 2023-2024 | Sprint Pns System |
| Biodelivery Sciences International, INC. | $38.10 | 2021 | |
| Nevro Corp. | $32.87 | 2023 | Senza |
| Abbvie INC. | $26.35 | 2022 | |
| Fidia Pharma USA INC. | $24.73 | 2023 | Hymovis |
| Avanos Medical | $22.63 | 2023 | Trivisc Sodium Hyaluronate |
| Otto Bock Healthcare LP | $21.51 | 2024 | |
| Depuy Synthes Sales INC. | $16.60 | 2024 | Orthovisc, Monovisc |
| Almatica Pharma LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Janisch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.